Genetic Testing Not Cost-effective In Guiding Initial Dosing Of Common Blood Thinner
Thursday, January 22, 2009 - 17:35
in Health & Medicine
New analyses show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding.